IOL Chemicals and Pharmaceuticals Past Earnings Performance
Past criteria checks 1/6
IOL Chemicals and Pharmaceuticals's earnings have been declining at an average annual rate of -29%, while the Pharmaceuticals industry saw earnings growing at 13.6% annually. Revenues have been growing at an average rate of 3.3% per year. IOL Chemicals and Pharmaceuticals's return on equity is 6%, and it has net margins of 4.9%.
Key information
-29.0%
Earnings growth rate
-29.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 3.3% |
| Return on equity | 6.0% |
| Net Margin | 4.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Investors Still Aren't Entirely Convinced By IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Earnings Despite 26% Price Jump
Dec 20
IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Has A Somewhat Strained Balance Sheet
Nov 19A Piece Of The Puzzle Missing From IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Share Price
Sep 11Is There An Opportunity With IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) 34% Undervaluation?
Jun 12Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?
Aug 30IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Has A Pretty Healthy Balance Sheet
May 18IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Will Pay A Dividend Of ₹4.00
Feb 10Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?
Jun 07Calculating The Intrinsic Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)
May 07Do IOL Chemicals and Pharmaceuticals's (NSE:IOLCP) Earnings Warrant Your Attention?
May 04Is IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP) An Attractive Dividend Stock?
Mar 13Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?
Feb 23Should You Rely On IOL Chemicals and Pharmaceuticals' (NSE:IOLCP) Earnings Growth?
Feb 08IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Jan 27How Does IOL Chemicals and Pharmaceuticals' (NSE:IOLCP) CEO Salary Compare to Peers?
Jan 15Estimating The Intrinsic Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)
Jan 02
Shareholders of IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Must Be Delighted With Their 869% Total Return
Dec 21Is Now The Time To Put IOL Chemicals and Pharmaceuticals (NSE:IOLCP) On Your Watchlist?
Dec 09These 4 Measures Indicate That IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Is Using Debt Reasonably Well
Nov 24IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Could Be A Buy For Its Upcoming Dividend
Nov 12Is There More To The Story Than IOL Chemicals and Pharmaceuticals's (NSE:IOLCP) Earnings Growth?
Nov 09Will Weakness in IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Stock Prove Temporary Given Strong Fundamentals?
Oct 27Here's What We Think About IOL Chemicals and Pharmaceuticals' (NSE:IOLCP) CEO Pay
Oct 09Calculating The Fair Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)
Sep 18Here's Why I Think IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Might Deserve Your Attention Today
Sep 03Cautious Investors Not Rewarding IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Performance Completely
Aug 16Revenue & Expenses Breakdown
How IOL Chemicals and Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 20,524 | 998 | 2,114 | 0 |
| 30 Jun 24 | 20,720 | 1,185 | 2,017 | 0 |
| 31 Mar 24 | 21,328 | 1,344 | 2,027 | 0 |
| 31 Dec 23 | 22,161 | 1,716 | 1,938 | 0 |
| 30 Sep 23 | 22,192 | 1,723 | 1,873 | 0 |
| 30 Jun 23 | 22,153 | 1,503 | 1,787 | 0 |
| 31 Mar 23 | 22,171 | 1,391 | 1,686 | 0 |
| 31 Dec 22 | 22,024 | 1,041 | 1,633 | 0 |
| 30 Sep 22 | 22,341 | 1,204 | 1,567 | 0 |
| 30 Jun 22 | 22,305 | 1,353 | 1,518 | 0 |
| 31 Mar 22 | 21,840 | 1,677 | 1,415 | 0 |
| 31 Dec 21 | 20,719 | 2,132 | 1,350 | 0 |
| 30 Sep 21 | 20,298 | 2,879 | 1,280 | 0 |
| 30 Jun 21 | 20,254 | 3,840 | 1,251 | 0 |
| 31 Mar 21 | 19,670 | 4,446 | 1,157 | 0 |
| 31 Dec 20 | 19,481 | 4,596 | 1,104 | 0 |
| 30 Sep 20 | 19,463 | 4,428 | 1,062 | 0 |
| 30 Jun 20 | 18,618 | 4,035 | 975 | 0 |
| 31 Mar 20 | 18,945 | 3,613 | 974 | 0 |
| 31 Dec 19 | 18,753 | 3,727 | 923 | 0 |
| 30 Sep 19 | 18,423 | 3,569 | 904 | 0 |
| 30 Jun 19 | 18,163 | 3,076 | 855 | 0 |
| 31 Mar 19 | 16,853 | 2,367 | 794 | 0 |
| 31 Dec 18 | 15,506 | 1,465 | 736 | 0 |
| 30 Sep 18 | 13,350 | 731 | 657 | 0 |
| 30 Jun 18 | 11,298 | 391 | 605 | 0 |
| 31 Mar 18 | 9,833 | 277 | 562 | 0 |
| 31 Dec 17 | 8,891 | 178 | 526 | 0 |
| 30 Sep 17 | 8,094 | 100 | 495 | 0 |
| 30 Jun 17 | 8,265 | 65 | 26 | 0 |
| 31 Mar 17 | 7,107 | 47 | 433 | 0 |
| 31 Dec 16 | 6,595 | 39 | 436 | 0 |
| 30 Sep 16 | 6,197 | -74 | 407 | 0 |
| 30 Jun 16 | 6,055 | -214 | 382 | 0 |
| 31 Mar 16 | 5,804 | -400 | 352 | 0 |
| 31 Dec 15 | 5,131 | -692 | 386 | 0 |
| 30 Sep 15 | 4,377 | -890 | 363 | 0 |
| 30 Jun 15 | 4,008 | -858 | 261 | 0 |
| 31 Mar 15 | 3,847 | -667 | 248 | 0 |
| 31 Dec 14 | 4,405 | -378 | 277 | 0 |
| 30 Sep 14 | 5,115 | -71 | 281 | 0 |
| 30 Jun 14 | 5,452 | 37 | 271 | 0 |
| 31 Mar 14 | 5,635 | 33 | 398 | 0 |
Quality Earnings: IOLCP has high quality earnings.
Growing Profit Margin: IOLCP's current net profit margins (4.9%) are lower than last year (7.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IOLCP's earnings have declined by 29% per year over the past 5 years.
Accelerating Growth: IOLCP's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: IOLCP had negative earnings growth (-42.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20.6%).
Return on Equity
High ROE: IOLCP's Return on Equity (6%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/23 03:39 |
| End of Day Share Price | 2025/01/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
IOL Chemicals and Pharmaceuticals Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Antique Stockbroking Ltd. |
| Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |
| Kameswari V. S. Chavali | FirstCall Research |